Want to see TSE:NEVI full AI Analyst Report?
NEVI Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.10
Previous CloseN/A
Volume20.00K
Average Volume (3M)55.49K
Market Cap
C$594.94K
Enterprise ValueC$1.32
Total Cash (Recent Filing)C$60.85K
Total Debt (Recent Filing)C$394.63K
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Oct 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume84,932
30 Day Avg. Volume55,489
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross-Margin ImprovementThe substantial gross-margin improvement indicates better unit economics or product mix. If maintained, it could provide a foundation for narrowing operating losses, although stronger revenue and cost control are still needed to convert this benefit into profitability.
Positive Cash GenerationThe shift to positive operating and free cash flow improves near-term financial resilience and reduces reliance on external funding. This is a meaningful improvement over prior periods, though its durability depends on stabilizing revenue and limiting ongoing losses.
Manageable LeverageLow leverage and positive equity provide greater financial flexibility than a highly indebted balance sheet. This can help the company fund operations and absorb volatility, although persistent losses could gradually weaken equity if profitability does not improve.
Bears Say
Sharp Revenue ContractionA sharply shrinking top line is a fundamental concern because it limits operating leverage, weakens market traction, and makes fixed costs harder to absorb. Sustained contraction could offset gross-margin gains and keep the business dependent on additional financing.
Persistent LossesOngoing net losses show that the business has not yet reached a sustainable earnings model. Negative returns on equity also indicate that shareholder capital is not generating value, and continued losses could erode the recently positive equity base.
Weak Cash-Flow SustainabilityAlthough cash flow is currently positive, declining free cash flow and modest cash conversion suggest the improvement may not be durable. Limited cash generation relative to revenue leaves less capacity to fund growth, absorb setbacks, or offset operating losses.
Pascal Biosciences Inc News
NEVI FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.01 and its highest was C$0.10 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is C$594.94K.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Oct 16, 2026 which is in 55 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Pascal Biosciences Inc released its earnings results on Jul 16, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Pascal Biosciences Inc reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:NEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―